Clinical trials: Eye Injuries
Multiple Sclerosis, Relapsing-Remitting
A Post-Authorization, Long-term Study of Ozanimod Real-world Safety
The purpose of this study is to determine the rates of adverse events of interest (AEIs) in a real-world population of participants with relapsing remitting multiple sclerosis (RRMS) receiving Ozanimod, sphingosine-1 phosphate…
- Trial name
- ORION (NCT05605782)
- Where
- United States
- Volunteers
- 9,000 people
- Sponsor
- Bristol-Myers Squibb
Corneal Epithelial Disorders
Safety and Efficacy Study of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders
The purpose of the study is to determine if SJP-0035 ophthalmic solution is effective in promoting corneal epithelial wound healing in conditions associated with corneal epithelial disorders.
- Trial name
- NCT02104388
- Testing
- SJP-0035 Ophthalmic Solution, Vehicle of SJP-0035 Ophthalmic Solution
- Where
- 17 sites in United States
- Volunteers
- 69 people
- Sponsor
- Senju Pharmaceutical Co., Ltd.
Retinopathy of Prematurity (ROP)
IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity
To compare the severity of retinopathy of prematurity (ROP) among treated infants with an untreated control population, matched for gestational age at birth while confirming the dose of rhIGF-1/rhIGFBP-3 is safe and efficacious.
- Trial name
- NCT01096784
- Testing
- rhIGF-I/rhIGFBP-3
- Where
- 24 sites in United States, Italy and 4 more
- Volunteers
- 121 people
- Sponsor
- Shire
Corneal Persistent Epithelial Defect
NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Injuries
This study will enroll participants with a non-infected, corneal persistent epithelial defect (PED) resulting from an ocular chemical and/or thermal ocular injury which is non-responsive or refractory to current standard of care…
- Trial name
- EXPEDE (NCT04081103)
- Testing
- Nexagon® (lufepirsen) High Dose Concentration, Nexagon® (lufepirsen) Low Dose Concentration, Vehicle
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Glaukos Corporation
Homonymous Hemianopsia, Homonymous Quadrantanopia
PAVE (Parallactic Visual-Field Enhancement) System for Treatment of Chronic Visual Field Loss Due to Stroke, Traumatic Brain Injury, or Brain Surgery
This is a research study to evaluate the effectiveness of the PAVE (Parallactic Visual-Field Enhancement) System for the treatment of chronic visual field loss due to stroke, traumatic brain injury, or brain surgery.
- Trial name
- NCT07185971
- Testing
- PAVE (Parallactic Visual-Field Enhancement) treatment using a virtual reality head mounted display
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- NeuroAEye LLC
Retinopathy of Prematurity (ROP), Intraventricular Hemorrhage
Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants
The purpose of this study is to evaluate long-term safety and efficacy outcomes following previously administered short-term exposure to SHP607, as compared to a standard neonatal care group.
- Conditions
- Retinopathy of Prematurity (ROP), Intraventricular Hemorrhage, Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity
- Trial name
- NCT04506619
- Testing
- No Intervention
- Where
- 8 sites in United States, Italy and 1 more
- Volunteers
- 26 people
- Sponsor
- Oak Hill Bio Ltd
Eyes Dry Chronic, Chronic Conjunctivitis of Both Eyes
CDL Validation Study
Ocular surface photography is significantly limited in standardization and reproducibility. This reduces its applicability for clinical monitoring of acute or chronic disease.
- Conditions
- Eyes Dry Chronic, Chronic Conjunctivitis of Both Eyes, Limbal Stem-cell Deficiency, Eye Lesion
- Trial name
- NCT05461469
- Where
- Austria
- Volunteers
- 104 people
- Sponsor
- Occyo GmbH
Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral…
- Conditions
- Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin
- Trial name
- ON-5001 (NCT06022029)
- Testing
- ONM-501, Cemiplimab
- Where
- 16 sites in United States, Australia
- Volunteers
- 168 people
- Sponsor
- OncoNano Medicine, Inc.
Non-arteritic Ischemic Optic Neuropathy, Optic Nerve Injuries
Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).
The study objectives are to assess any changes in visual acuity and visual field observed following the administration of RPh201 during an overall treatment period of at least 13 consecutive weeks with an option to extended the…
- Trial name
- NCT02045212
- Testing
- RPh201
- Where
- Israel
- Volunteers
- 22 people
- Sponsor
- Regenera Pharma Ltd
Corneal Disease, Corneal Opacity
Study to Evaluate the Clinical Safety and Performance of the CorNeat KPro for Treatment of Corneal Blindness
A Single Arm, Pivotal, Open Label, Multicenter Clinical Investigation to Evaluate the Clinical Safety and Performance of the CorNeat Keratoprosthesis, for Treatment of Corneal Blindness
- Conditions
- Corneal Disease, Corneal Opacity, Corneal Injuries
- Trial name
- NCT05694247
- Testing
- CorNeat KPro
- Where
- 6 sites in Canada, France and 2 more
- Volunteers
- 15 people
- Sponsor
- CorNeat Vision Ltd.
Allergic Conjunctivitis
Safety and Efficacy Study of AL-53817 and AL-78843 Ophthalmic Solutions for Allergic Conjunctivitis
The purpose of this study is to evaluate two investigational ophthalmic solutions for reduction in ocular redness in subjects with allergic conjunctivitis.
- Trial name
- NCT02079649
- Testing
- AL-53817 Ophthalmic Solution, 0.1%, AL-78843 Ophthalmic Solution, 0.03%, Dexamethasone Ophthalmic Suspension, 0.1%
- Volunteers
- 224 people
- Sponsor
- Alcon Research
Ocular Injury
An Observational, Qualitative Study Assessing Eye Drop Administration
This is a prospective, observational, consecutive, qualitative, multicenter study. Based on the available published evidence that supports patient challenges with eyedrop administration, the purpose of this video-capture study is…
- Trial name
- NCT05307081
- Testing
- Artificial Tears
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Ocular Therapeutix, Inc.
Wave Form Signals Coming From the Eye in a Healthy Cohort
Neuro-ocular Baselines in a Sports Setting
Rebion (Rebiscan, Inc) has developed a noninvasive, handheld device that uses retinal birefringence scanning (RBS) to rapidly assess eye fixation and retinal integrity in adults and children.
- Trial name
- KY (NCT03653936)
- Testing
- HITT device
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Rebiscan, Inc.
Persistent Epithelial Defect
A Study to Investigate the Safety and Clinical Effect of Nexagon® to Treat Persistent Epithelial Defects
The purpose of this study is to evaluate the efficacy and safety of Nexagon® in subjects with Persistent Epithelial Defects (PED) originally caused by chemical burns.
- Trial name
- NCT00821561
- Testing
- Nexagon®, Nexagon® vehicle
- Volunteers
- 90 people
- Sponsor
- OcuNexus Therapeutics, Inc.
MTBI - Mild Traumatic Brain Injury, Vestibular Disease
Effectiveness of VestAid App
This multi-center randomized trial (MCRT) will investigate the effectiveness of the VestAid application to provide equivalent or faster recovery from dizziness compared to standard-of-care delivery of vestibular rehabilitation…
- Conditions
- MTBI - Mild Traumatic Brain Injury, Vestibular Disease, Balance Deficits, Vestibular Disorders
- Trial name
- NCT06683417
- Testing
- Vestibular Rehabilitation Aid, Standard of care vestibular rehabilitation
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- BlueHalo
Corneal Scar
Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars
This study will enroll subjects with recently formed corneal scars that resulted from a corneal insult presenting and diagnosed within the past approximately 30 days and not less than approximately 7 days.
- Trial name
- NCT06257355
- Testing
- CSB-001 Ophthalmic Solution 0.1%
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Claris Biotherapeutics, Inc.
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable
Quest to Analyze One Thousand Humans Meditating
This study will be focused on assessing the molecular, physiological, and emotional correlates of an intensive meditation experience in the context of a retreat setting in a large 2000 plus-person cohort comprised of healthy and…
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma
- Trial name
- QUANTUM (NCT06583395)
- Testing
- Advanced multi-component meditation practice
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Tobias Moeller-Bertram
PTSD
Senseye's OBCI Diagnostic Tool for PTSD
This pilot study will investigate the feasibility, acceptability, repeatability, accuracy and efficacy of the Senseye OBCI diagnostic tool to assess the presence and severity of PTSD symptoms and monitor response to…
- Trial name
- NCT05372523
- Testing
- CAPS-5 Assessment, Senseye OBCI
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Senseye, Inc.
Neurologic Disorders, Nervous System Diseases
Neurologic Stem Cell Treatment Study
This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will…
- Conditions
- Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders
- Trial name
- NEST (NCT02795052)
- Testing
- Intravenous and Intranasal BMSC
- Where
- 3 sites in United States, United Arab Emirates
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Blindness
A Study to Evaluate the BrainPort Vision Device in Individuals Blinded by Traumatic Injury
The BrainPort V200 Device is a wearable, non-surgical, prosthetic device intended for people who are profoundly blind. The BrainPort V200 translates images captured by a digital camera into electro-tactile stimulation presented…
- Trial name
- NCT02393118
- Testing
- BrainPort V200 Device
- Where
- 3 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Wicab